Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VXRT

VXRT - Vaxart Inc Stock Price, Fair Value and News

0.67USD-0.01 (-1.47%)Market Closed

Market Summary

VXRT
USD0.67-0.01
Market Closed
-1.47%

VXRT Alerts

  • 1 major insider buys recently.

VXRT Stock Price

View Fullscreen

VXRT RSI Chart

VXRT Valuation

Market Cap

118.5M

Price/Earnings (Trailing)

-1.45

Price/Sales (Trailing)

13.33

EV/EBITDA

-1.26

Price/Free Cashflow

-1.74

VXRT Price/Sales (Trailing)

VXRT Profitability

Operating Margin

-396.34%

EBT Margin

-916.88%

Return on Equity

-146.78%

Return on Assets

-92.19%

Free Cashflow Yield

-57.35%

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

223.11%

Rev. Growth (Qtr)

-32.79%

VXRT Earnings

Earnings (TTM)

-81.7M

Earnings Growth (Yr)

2.88%

Earnings Growth (Qtr)

-40.53%

Breaking Down VXRT Revenue

Last 30 days

-1.5%

Last 90 days

-11.8%

Trailing 12 Months

-15.2%

How does VXRT drawdown profile look like?

VXRT Financial Health

Current Ratio

3.14

VXRT Investor Care

Shares Dilution (1Y)

30.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20248.9M000
2023697.0K2.1M4.2M7.4M
2022471.0K359.0K159.0K107.0K
20211.6M1.2M1.2M892.0K
20207.4M7.8M7.6M4.0M
20198.1M7.5M7.7M9.9M
20185.0M3.8M3.2M4.2M
20175.3M3.2M6.6M5.8M
2016011.5M9.4M7.4M
201523.5M8.4M13.6M0
201469.5M68.7M53.6M38.5M
201324.9M33.6M44.4M52.5M
201214.0M10.9M11.2M19.5M
201130.4M29.3M18.1M16.1M
2010018.7M26.8M35.0M
200900010.5M

Tracking the Latest Insider Buys and Sells of Vaxart Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 18, 2024
watson w. mark
bought
13,578
0.6789
20,000
-
Jun 12, 2024
lee phillip e
sold (taxes)
-1,525
0.76
-2,007
chief financial officer
Jun 11, 2024
watson w. mark
acquired
-
-
16,000
-
Jun 11, 2024
finney michael j.
acquired
-
-
16,000
-
Jun 11, 2024
wheadon david e.
acquired
-
-
16,000
-
Jun 11, 2024
yedid robert a.
acquired
-
-
16,000
-
Jun 11, 2024
heron elaine j
acquired
-
-
16,000
-
Mar 28, 2024
cummings james f.
sold (taxes)
-4,279
1.3
-3,292
chief medical officer
Mar 28, 2024
tucker sean
sold (taxes)
-5,072
1.3
-3,902
svp, chief scientific officer
Mar 18, 2024
cummings james f.
acquired
-
-
90,000
chief medical officer

1–10 of 50

Which funds bought or sold VXRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
reduced
-2.09
-129,986
131,337
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-0.78
-10,753
11,161
-%
Jul 16, 2024
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
unchanged
-
-6,458
6,810
-%
Jul 16, 2024
Mesirow Financial Investment Management, Inc.
sold off
-100
-13,000
-
-%
Jul 16, 2024
AdvisorNet Financial, Inc
unchanged
-
-443
467
-%
Jul 15, 2024
Sequoia Financial Advisors, LLC
new
-
64,729
64,729
-%
Jul 12, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
unchanged
-
-127
133
-%
Jul 10, 2024
NBC SECURITIES, INC.
sold off
-100
-1,000
-
-%
Jul 09, 2024
KINGSWOOD WEALTH ADVISORS, LLC
unchanged
-
-15,818
16,682
-%
Jul 08, 2024
Birch Capital Management, LLC
unchanged
-
-21.00
22.00
-%

1–10 of 47

Are Funds Buying or Selling VXRT?

Are funds buying VXRT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VXRT
No. of Funds

Unveiling Vaxart Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.63%
7,044,971
SC 13G/A
Jan 19, 2024
ra capital management, l.p.
9.1%
15,384,615
SC 13G
Jul 07, 2023
blackrock inc.
1.3%
1,928,709
SC 13G/A
Feb 09, 2023
vanguard group inc
5.35%
7,019,507
SC 13G
Feb 01, 2023
blackrock inc.
6.7%
8,858,225
SC 13G/A
Jan 10, 2023
state street corp
1.83%
2,398,264
SC 13G/A
Mar 10, 2022
state street corp
10.39%
13,072,021
SC 13G/A
Feb 11, 2022
state street corp
8.91%
11,187,642
SC 13G/A
Feb 07, 2022
blackrock inc.
6.7%
8,452,420
SC 13G
Feb 11, 2021
state street corp
8.63%
9,444,967
SC 13G

Recent SEC filings of Vaxart Inc

View All Filings
Date Filed Form Type Document
Jul 05, 2024
8-K
Current Report
Jul 03, 2024
S-8
Employee Benefits Plan
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
8-K/A
Current Report
Jun 18, 2024
8-K
Current Report
Jun 17, 2024
424B5
Prospectus Filed
Jun 14, 2024
8-K
Current Report
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
8-K
Current Report
Jun 13, 2024
8-K
Current Report

Peers (Alternatives to Vaxart Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Vaxart Inc News

Latest updates
MarketBeat12 Jul 202409:37 pm

Vaxart Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-32.8%2,181,0003,245,0002,101,0001,358,000675,00022,000--85,00074,000200,000112,000506,000356,000265,000523,0002,902,0003,916,000454,00085,0005,407,000
Operating Expenses30.3%26,251,00020,145,00019,923,00024,411,00026,247,00031,160,00029,426,00029,247,00024,861,00024,289,00017,451,00015,887,00016,017,00013,717,0007,854,0009,049,0003,596,0009,542,0005,168,0005,082,0005,855,000
  S&GA Expenses33.1%7,238,0005,440,0004,921,0005,598,0006,625,0006,447,0006,960,0009,321,0006,658,0005,754,0005,042,0005,150,0005,944,0005,126,0004,190,0003,896,0001,990,0001,331,0001,455,0001,375,0002,026,000
  R&D Expenses29.3%19,013,00014,705,00015,002,00018,813,00019,622,00020,459,00022,466,00019,926,00018,203,00015,530,00012,409,00010,737,00010,073,0008,591,0004,616,0005,114,0001,542,0003,291,0003,713,0003,707,0003,829,000
EBITDA Margin17.9%-8.19-9.97-19.42-45.33-144-952-625-245-159-74.16-50.74-40.71---------
Interest Expenses------------------27,00084,00097,000107,000
Income Taxes-74.1%45,000174,00039,00019,00029,00016,00016,00015,00020,00018,00021,00030,00038,00033,00026,00026,000153,000196,00031,00013,000250,000
Earnings Before Taxes-41.7%-24,372,000-17,201,000-17,361,000-22,531,000-25,111,000-23,902,000-29,293,000-29,415,000-25,081,000-20,746,000-17,562,000-16,086,000-15,969,000-13,828,000-8,059,000-8,951,000-1,144,000-6,213,000-5,229,000-5,624,000-1,089,000
EBT Margin17.7%-9.17-11.14-21.39-49.07-154-1,006-657-258-168-78.88-54.04-43.54---------
Net Income-40.5%-24,417,000-17,375,000-17,400,000-22,550,000-25,140,000-23,918,000-29,309,000-29,430,000-25,101,000-20,764,000-17,583,000-16,116,000-16,007,000-13,861,000-8,085,000-8,977,000-1,297,000-6,409,000-5,260,000-5,637,000-1,339,000
Net Income Margin17.7%-9.20-11.18-21.42-49.11-154-1,007-657-258-168-79.00-54.15-43.64---------
Free Cashflow-58.9%-21,322,000-13,417,000-15,283,000-17,925,000-25,699,000-33,053,000-16,643,000-28,225,000-26,459,000-16,829,000-15,591,000-15,362,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-3.4%89.0092.0010612313015417518120022124122920615315564.0053.0037.0043.0037.0036.00
  Current Assets-2.7%44.0046.0057.0071.0076.0099.0012013815416919218917512913646.0034.0018.0021.0017.0015.00
    Cash Equivalents-23.1%27.0035.0033.0043.0047.0046.0051.0091.0012314416716515712713344.0030.0014.0020.0016.008.00
  Net PPE-5.4%11.0012.0013.0014.0014.0016.0012.009.008.007.005.004.002.001.001.000.000.000.001.002.002.00
  Goodwill0.2%5.005.005.005.005.005.005.005.005.005.00-----------
Liabilities-3.1%33.0034.0034.0038.0040.0043.0053.0038.0034.0034.0036.0029.0030.0029.0023.0024.0021.0024.0024.0021.0024.00
  Current Liabilities2.9%14.0014.0011.0014.0016.0018.0022.0016.0011.0011.0013.0013.0012.0012.0010.0011.007.009.009.007.009.00
Shareholder's Equity-3.7%56.0058.0072.0085.0090.0011112214316618820520017612313240.0031.0013.0019.0016.0013.00
  Retained Earnings-6.0%-433-409-392-374-352-327-303-273-244-219-198-181-164-148-135-126-117-116-110-104-99.35
  Additional Paid-In Capital4.8%490468464460442438426417411407404381341272267167142130125119111
Accumulated Depreciation13.2%8.007.00-------------------
Shares Outstanding15.0%177153152152135134126126126126120118---------
Float----110---394---913---842---8.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-56.7%-21,191-13,521-15,001-17,471-24,460-29,152-14,615-25,899-25,113-15,814-14,267-13,159-16,592-10,766-9,255-521-3,208-3,792-4,328-317-4,653
  Share Based Compensation10.8%4,1163,7153,8433,9272,6473,3933,6433,4213,1302,9132,0992,6041,2514879152,86096.00137146180164
Cashflow From Investing-133.3%-5,02415,1044,970-1,58325,46115,801-31,073-8,8753,732-8,177-4,412-15,949-20,559-902-308-9.00-1.00-12.00-127-159-552
Cashflow From Financing27668.2%18,195-66.00-8.0013,8971,4208,5964,9882,8381,04050520,64437,06367,5925,10098,61315,05919,542-2,2287,7558,3102,123
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VXRT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues$ 2,181$ 675
Operating expenses:  
Research and development19,01319,622
General and administrative7,2386,625
Total operating expenses26,25126,247
Operating loss(24,070)(25,572)
Other income (expense):  
Interest income503642
Non-cash interest expense related to sale of future royalties(804)(178)
Other expense, net(1)(3)
Loss before income taxes(24,372)(25,111)
Provision for income taxes4529
Net loss$ (24,417)$ (25,140)
Net loss per share - basic and diluted (in dollars per share)$ (0.14)$ (0.19)
Shares used to compute net loss per share - basic and diluted (in shares)168,811,095135,213,196
Comprehensive loss:  
Net loss$ (24,417)$ (25,140)
Unrealized (loss) gain on available-for-sale investments, net of tax(9)229
Comprehensive loss(24,426)(24,911)
Non Cash Royalty Revenue [Member]  
Revenues585278
Government Contract [Member]  
Revenues1,5960
Grant [Member]  
Revenues$ 0$ 397

VXRT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 26,735$ 34,755
Short-term investments9,9294,958
Accounts receivable5563,008
Prepaid expenses and other current assets7,0642,815
Total current assets44,28445,536
Property and equipment, net11,10211,731
Right-of-use assets, net23,75324,840
Intangible assets, net4,1064,289
Goodwill4,5084,508
Other long-term assets917926
Total assets88,67091,830
Current liabilities:  
Accounts payable3,9781,584
Other accrued current liabilities4,9805,634
Current portion of operating lease liability2,7992,703
Current portion of liability related to sale of future royalties2,3603,803
Total current liabilities14,11713,724
Operating lease liability, net of current portion16,69117,385
Liability related to sale of future royalties, net of current portion1,8632,623
Other long-term liabilities309293
Total liabilities32,98034,025
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock: $0.0001 par value; 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 177,187,965 shares issued and 176,523,042 shares outstanding as of March 31, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 20231815
Additional paid-in capital490,221467,731
Treasury stock at cost, 664,923 shares as of March 31, 2024 and 507,020 shares as of December 31, 2023(548)(366)
Accumulated deficit(433,991)(409,574)
Accumulated other comprehensive loss(10)(1)
Total stockholders’ equity55,69057,805
Total liabilities and stockholders’ equity$ 88,670$ 91,830
VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://vaxart.com
 INDUSTRYBiotechnology
 EMPLOYEES164

Vaxart Inc Frequently Asked Questions


What is the ticker symbol for Vaxart Inc? What does VXRT stand for in stocks?

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxart Inc (VXRT)?

As of Fri Jul 19 2024, market cap of Vaxart Inc is 118.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers. The fair value of Vaxart Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxart Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VXRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxart Inc a good stock to buy?

The fair value guage provides a quick view whether VXRT is over valued or under valued. Whether Vaxart Inc is cheap or expensive depends on the assumptions which impact Vaxart Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VXRT.

What is Vaxart Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, VXRT's PE ratio (Price to Earnings) is -1.45 and Price to Sales (PS) ratio is 13.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vaxart Inc's stock?

In the past 10 years, Vaxart Inc has provided -0.323 (multiply by 100 for percentage) rate of return.